RESUMO
Disruption of p53-MDM2/MDMX interaction by smaller inhibitors is a promising therapeutic intervention gaining tremendous interest. However, no MDM2/MDMX inhibitors have been marketed so far. Drug repurposing is a validated, practical approach to drug discovery. In this regard, we employed structure-based virtual screening in a reservoir of marketed drugs and identified nintedanib as a new MDM2/MDMX dual inhibitor. The computational structure analysis and biochemical experiments uncover that nintedanib binds MDM2/MDMX similarly to RO2443, a dual MDM2/MDMX inhibitor. Furthermore, the mechanistic study reveals that nintedanib disrupts the physical interaction of p53-MDM2/MDMX, enabling the transcriptional activation of p53 and the subsequent cell cycle arrest and growth inhibition in p53+/+ cancer cells. Lastly, structural minimisation of nintedanib yields H3 with the equivalent potency. In summary, this work provides a solid foundation for reshaping nintedanib as a valuable lead compound for the further design of MDM2/MDMX dual inhibitors.
Assuntos
Antineoplásicos , Proteínas Proto-Oncogênicas c-mdm2 , Proteínas Proto-Oncogênicas c-mdm2/química , Proteínas Proto-Oncogênicas c-mdm2/metabolismo , Proteínas Proto-Oncogênicas/química , Proteínas Proto-Oncogênicas/metabolismo , Proteína Supressora de Tumor p53/metabolismo , Reposicionamento de Medicamentos , Antineoplásicos/farmacologia , Antineoplásicos/química , Ligação ProteicaRESUMO
OBJECTIVE: To investigate predictors of anticoagulation efficacy in deep venous thrombosis (DVT) by ultrasound elastography (UE). METHODS: The basic clinical, laboratory and ultrasound treatment data of fifty-eight patients with DVT were collected and analyzed. Then the results of ultrasound after 3-month anticoagulation treatment were compared among different groups. Multiple logistic regression analysis was used to identify independent risk factors that affected anticoagulation efficacy. The predictive efficacy of each independent risk factor was accessed by drawing operating characteristic (ROC) curves. RESULTS: According to the regression analysis, the elastic modulus (ORâ=â0.631, Pâ=â0.001) and strain rate ratio (ORâ=â0.332, Pâ=â0.006) were identified as independent risk factors for the effectiveness of anticoagulation therapy in patients with DVT. According to the ROC curves, elastic modulus and strain rate ratio could predict effective anticoagulation therapy for DVT, and the optimal threshold values were 22.10âkPa and 1.80 respectively. The corresponding AUC values were 0.879 and 0.854, with a sensitivity of 71.4% and 59.5%, a specificity of 93.7%, and a Youden index of 65.1% and 62.7%, respectively. CONCLUSIONS: The elastic modulus (≤22.10âkPa) or strain rate ratio (≤1.80) of the thrombus were independent predictors for the effectiveness of anticoagulation therapy.
Assuntos
Anticoagulantes , Técnicas de Imagem por Elasticidade , Extremidade Inferior , Trombose Venosa , Humanos , Trombose Venosa/diagnóstico por imagem , Trombose Venosa/tratamento farmacológico , Técnicas de Imagem por Elasticidade/métodos , Masculino , Anticoagulantes/uso terapêutico , Feminino , Pessoa de Meia-Idade , Extremidade Inferior/irrigação sanguínea , Extremidade Inferior/diagnóstico por imagem , Adulto , Idoso , Fatores de RiscoRESUMO
Isoflavones are commonly found in diets, such as soybean and clover. Their anti-inflammatory effects are due to the inhibition of the transcriptional regulation of NF-κB. Hydrogenated isoflavones are metabolites of isoflavones with higher bioavailability, however, there have been few studies on their anti-inflammatory effects. In this work, by using the LPS-stimulated RAW264.7 cell model, we investigated the anti-inflammatory effect and the underlying mechanism of hydrogenated isoflavones. Hydrogenated isoflavones reduced the production of LPS-stimulated pro-inflammatory mediators and enzymes, including TNF-α, IL-6, NO, iNOS and COX-2. The level of ROS was also diminished in LPS-stimulated RAW264.7 cells. Further mechanistic studies showcase that hydrogenated isoflavones block NF-κB and MAPK pathways via attenuation of p65 nuclear translocation and JNK, ERK, and p38 phosphorylation, respectively. In addition, we found that hydrogenated isoflavones display anti-proliferation effect in human colon cancer cells with wild-type p53. Together, hydrogenated isoflavones could be used as an adjuvant for the treatment of inflammation and cancer.
Assuntos
Isoflavonas , NF-kappa B , Animais , Camundongos , Humanos , NF-kappa B/metabolismo , Lipopolissacarídeos/farmacologia , Lipopolissacarídeos/metabolismo , Transdução de Sinais , Isoflavonas/farmacologia , Anti-Inflamatórios/farmacologia , Sistema de Sinalização das MAP Quinases , Células RAW 264.7 , Óxido Nítrico/metabolismoRESUMO
In July 2022, the World Health Organization announced monkeypox as a public health emergency of international concern (PHEIC), and over 85,000 global cases have been reported currently. However, preventive and therapeutic treatments for the monkeypox virus (MPXV) remain limited. MPXV mRNA cap N7 methyltransferase (MTase) is composed of two subunits (E1 C-terminal domain (E1CTD) and E12) which are essential for the replication of MPXV. Here, we solved a 2.16 Å crystal structure of E12. We also docked the D1CTD of the vaccinia virus (VACV) corresponding to the E1CTD in MPXV with E12 and found critical residues at their interface. These residues were further used for drug screening. After virtual screening, the top 347 compounds were screened out and a list of top 20 potential MPXV E12 inhibitors were discovered, including Rutin, Quercitrin, Epigallocatechin, Rosuvastatin, 5-hydroxy-L-Tryptophan, and Deferasirox, etc., which were potential E12 inhibitors. Taking the advantage of the previously unrecognized special structure of MPXV MTase composing of E1CTD and E12 heterodimer, we screened for inhibitors targeting MTase for the first time based on the interface between the heterodimer of MPXV MTase. Our study may provide insights into the development of anti-MPXV drugs.
Assuntos
Metiltransferases , Monkeypox virus , RNA Mensageiro , Metiltransferases/genética , Metiltransferases/química , Monkeypox virus/genética , GuaninaRESUMO
Coronavirus disease 2019 (COVID-19), caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has escalated into a global tragedy afflicting human health, life, and social governance. Through the increasing depth of research and a better understanding of this disease, it has been ascertained that, in addition to the lungs, SARS-CoV-2 can also induce injuries to other organs including the liver. Liver injury is a common clinical manifestation of COVID-19, particularly in severe cases, and is often associated with a poorer prognosis and higher severity of COVID-19. This review focuses on the general existing information on liver injury caused by COVID-19, including risk factors and subpopulations of liver injury in COVID-19, the association between preexisting liver diseases and the severity of COVID-19, and the potential mechanisms by which SARS-CoV-2 affects the liver. This review may provide some useful information for the development of therapeutic and preventive strategies for COVID-19-associated liver injury.